An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Clinical trial NCT04485260 · UNKNOWN
Trial details
- NCT number
- NCT04485260
- Sponsor
- Kartos Therapeutics, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-28
- Primary completion
- 2022-10-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.